Monday, August 15, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home Medicine

Revamped LDN site launched — biggest patient-initiated drug discovery program in history

March 16, 2016
in Medicine
0
Share on FacebookShare on Twitter

The MedInsight Research Institute, a non-profit organization dedicated to educating patients and physicians about non-commercially sponsored treatments for chronic and serious medical conditions, has launched a revamped LDN information website at LDNscience.org.

LDN, an acronym for low dose naltrexone, is the biggest patient-initiated drug discovery program in history. LDN involves using an FDA-approved opiate addiction treatment drug, naltrexone, at a very low dose to induce significant medical benefits among patients suffering from autoimmune diseases and other chronic medical conditions. A series of clinical trials has shown LDN to be useful for the treatment of Crohn's disease, multiple sclerosis (MS), fibromyalgia, HIV, Parkinson's and chronic pain. These studies have been carried out at major academic institutions including Penn State University, Stanford University, the University of California San Francisco, and SUNY Buffalo, among others.

After MedInsight initiated the first-ever clinical trial of LDN in patients with Crohn's disease, 13 additional clinical trials and 19 case reports about LDN have been published in medical literature to date.

"This is clear evidence of the great power consumers wield once we take responsibility for our own healthcare choices, and proceed to drive the changes we wish to see in medical research and practice. The success of LDN is a model for the kind of great patient-initiated advances that are possible," said Moshe Rogosnitzky, founder of LDNscience.org. "We are pleased to offer an even better resource for patients, families, doctors and researchers who are passionate about treating these serious conditions and enhancing quality of life."

LDNscience includes all the research to date about LDN, explanatory material for patients and doctors, a directory of doctors prescribing LDN, an FAQ section, interviews with LDN researchers and LDN users, and more.

"LDN is an unparalleled example of what consumer power and initiative can achieve. LDN offers hope for those who have failed standard therapies or find standard therapies too risky," Rogosnitzky added. "It is astounding that a pharmaceutical treatment with no commercial backing whatsoever has managed to reach 300,000 patients across the globe, despite not being approved yet by the health authorities in any country."

"We are grateful that LDNscience has played such a major role in educating consumers and physicians about a very safe therapy that has helped turn so many patients' lives around," said Shira Bienstock, content director at LDNscience. "Through our remodeled website and other projects in the pipeline, we look forward to contributing even more to the worldwide community regarding advances in low dose naltrexone research."

###

About LDNscience: LDNscience® is a public information project of the MedInsight Research Institute http://www.ldnscience.org

About MedInsight: MedInsight Research Institute is a U.S./ U.K.-based non-profit organization established in 2006 that serves as a platform for researching and indexing non-commercial off-label (repurposed) treatments for cancer and chronic diseases.

Media Contact

Shira Bienstock
[email protected]

Share25Tweet16Share4ShareSendShare
  • Amanda Poholek, Ph.D.

    Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

    136 shares
    Share 54 Tweet 34
  • Nuclear war would cause a global famine and kill billions, Rutgers-led study finds

    65 shares
    Share 26 Tweet 16
  • 1 in 3 parents worry that school traffic is a danger for kids

    64 shares
    Share 26 Tweet 16
  • Exercise answer: Research shows it’s how often you do it, not how much

    64 shares
    Share 26 Tweet 16
  • Null results research now published by major behavioral medicine journal

    384 shares
    Share 154 Tweet 96
  • The North American Menopause Society releases its 2022 Hormone Therapy Position Statement

    148 shares
    Share 59 Tweet 37
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Experts optimistic about converting coal plants to production of clean geothermal energy

A role for cell ‘antennae’ in managing dopamine signals in the brain

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 193 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In